VIDEO: Richard Stefanacci, DO, Addresses Cost Concerns of Neurodegenerative Diseases
Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases. One is the actual cost of the disease and the second is the cost of diagnostic testing. Dr Stefanacci also says that treatments are now currently inexpensive, but with new emerging therapiess the costs will rise.
This video was taken on Thursday, November 8 at the NAMCP Fall Forum in Las Vegas, NV.
Panelists discussed the price of pharmaceuticals and controlling the cost of care at the 64th Annual Roy A. Bowers Pharmaceutical Conference: A Measured Approach—Health Care Delivery and Transformation in a Metric Driven World, held by Rutgers University.
From the youngest patients to the oldest, the Affordable Care Act’s promise that care will be provided despite pre-existing conditions is bumping against the challenge of keeping costs in check. From around the country come reports of pushback, which evoke the 1990s stories of managed care’s debut: limited choice.
The era of accountable care and pay for performance is here, and physicians will have to embrace these novel reimbursement models. In a plenary session, Rubin Cohen, MD, FCCP, a member of the American College of Chest Physician’s quality improvement committee, discussed the relationship between quality improvement and outcomes.
A symposium on idiopathic pulmonary fibrosis (IPF), which was presented on behalf of InterMune, Inc, highlighted clinical data supporting the use of pirfenidone in patients with IPF. Leading the panel discussion was Steven Nathan, MD, FCCP, a principal investigator involved in studies of pirfenidone. Dr Nathan was joined by IPF experts Lisa Lancaster, MD, of Vanderbilt University Medical Center and Marilyn Glassberg, MD, of the University of Miami Health System.